Efficacy and tolerability of levetiracetam in children aged 10 years and younger: a clinical experience.
Levetiracetam is a new anti-epileptic drug that is currently not licensed for use in children. Studies in adults suggest that it may be a useful adjunctive treatment both in partial onset and generalised epilepsy. A retrospective case notes review of 26 children age 10 years and under with refractory epilepsy was undertaken to evaluate the efficacy and safety of the drug. The drug appeared to be most effective in children with partial onset seizures and least effective in those with myoclonic seizures. Sixty-one percent of patients showed a good response to levetiracetam with at least a 50% reduction in seizure frequency with two of these 26 children with previously refractory epilepsy becoming seizure-free. Levetiracetam was also found to be well-tolerated with very few reported side-effects.
The Roald Dahl EEG Unit, Department of Neurology, Royal Liverpool Children's Hospital (Alder Hey), Eaton Road, Liverpool L12 2AP, UK.
Maw J
MJ
Tan
Richard E
RE
Appleton
D000367:Age Factors; D002648:Child; D002675:Child, Preschool; D004827:Epilepsy / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D006801:Humans; D007223:Infant; D000077287:Levetiracetam; D008297:Male; D010889:Piracetam / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use*; D012189:Retrospective Studies
D000077287:Levetiracetam; D010889:Piracetam